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Protein misfolding, mitochondrial dysfunction and oxidative stress are common 
pathomechanisms that underlie neurodegenerative diseases. In prion disease, central to 
these processes is the post-translational transformation of cellular prion protein (PrPc) to 
the aberrant conformationally altered isoform; PrPSc. This can trigger oxidative reactions 
and impair mitochondrial function by increasing levels of peroxynitrite, causing damage 
through formation of hydroxyl radicals or via nitration of tyrosine residues on proteins. The 6 
member Peroxiredoxin (Prdx) family of redox proteins are thought to be critical protectors 
against oxidative stress via reduction of H2O2, hydroperoxides and peroxynitrite. In our in 
vitro studies cellular metabolism of SK-N-SH human neuroblastoma cells was significantly 
decreased in the presence of H2O2 (oxidative stressor) or CoCl2 (cellular hypoxia), but was 
rescued by treatment with exogenous Prdx6, suggesting that its protective action is in part 
mediated through a direct action. We also show that CoCl2-induced apoptosis was 
significantly decreased by treatment with exogenous Prdx6. We proposed a redox regulator 
role for Prdx6 in regulating and maintaining cellular homeostasis via its ability to control 
ROS levels that could otherwise accelerate the emergence of prion-related neuropathology. 
To confirm this, we established prion disease in mice with and without astrocyte-specific 
antioxidant protein Prdx6, and demonstrated that expression of Prdx6 protein in Prdx6 Tg 
ME7-animals reduced severity of the behavioural deficit, decreased neuropathology and 
increased survival time compared to Prdx6 KO ME7-animals. We conclude that antioxidant 
Prdx6 attenuates prion-related neuropathology, and propose that augmentation of 
endogenous Prdx6 protein represents an attractive adjunct therapeutic approach for 




Alzheimer’s and prion diseases are characterized by accumulation and deposition of misfolded 
proteins. In prion disease parallel with loss of subsets of nerve cells is an increase in non-neuronal 
cells (astrocytes) that can impact on their homeostasis. These astrocytes produce peroxiredoxin-6 
(Prdx6), a protective antioxidant protein constituent of specific pathways that are activated in 
response to the misfolding insult and could be highly beneficial to both neuronal and non-neuronal 
cells. We proposed a redox regulator role for Prdx6 in regulating and maintaining normal cell 
function via its ability to control the cell stressors, which would contribute to amelioration of prion 
pathology. To confirm this we generated diseased animals with and without Prdx6 protein. Upon 
onset of pathology we tested the animals behaviourally, and showed that there was improvement of 
behavioural deficit and rescue of survival in animals with Prdx6 (Prdx6 Tg) compared to animals 
without Prdx6 (Prdx6 KO). Neuropathology was attenuated in the brains of Prdx6KO animals 
compared to Prdx6 Tg animals with disease. Furthermore application of exogenous Prdx6 rescued 
toxicity due to a chemical inducer of oxidative stress and a chemical inducer of cellular hypoxia in 
cell culture. We contend that augmentation of endogenous Prdx6 protein represents an attractive 
adjunct therapeutic approach for acute and chronic degenerative diseases. 
 
















Alzheimer’s disease (AD), prion disease, and Parkinson's disease (PD) are chronic protein 
misfolding degenerative diseases characterised by an increase in the β-sheet content and 
brain accumulation of misfolded amyloid-β (Aβ), prion (scrapie) protein (PrPSc), and α-
synuclein respectively. This common theme in the pathogenesis of these disorders 
indicates that analogous degenerative processes are likely at play, and similar therapeutic 
strategies may be effective in these diseases. Early stages of these pathologies are 
characterized by localized loss of neuronal processes and synapses in the absence of overt 
neuron loss. The precise mechanisms of this selective synaptic degeneration is likely 
multifactorial (Kadish et al., 2009), involving inflammatory processes (Centonze et al., 
2009), and increase in reactive oxygen species (ROS) (Mast et al., 2008) induced by 
physiological and/or environmental stress, allied with deficiency in bioenergetics (Kikuchi et 
al., 2011; Saxena, 2011). The evidence linking inflammation to disease pathogenesis is 
significant; involving activated astrocytes and microglia in the vicinity of misfolded proteins, 
activation of the classical and alternative complement pathways, and increased secretion of 
inflammatory cytokines (Perry et al., 2010; Raine, 2000) that can create additional ROS and 
peroxynitrite (PN) (Vana et al., 2011). Their generation is associated with the activation or 
deactivation of transcription factors capable of regulating cell survival, and down-regulation 
of antioxidant genes (Fatma et al., 2001; Hildeman et al., 1999), which in turn disrupts 
cellular integrity. Abnormally folded proteins implicated in degenerative diseases also 
demonstrably generate ROS, and H2O2 (Hensley et al., 1994; Huang et al., 1999; Pietri et 
al., 2006; Tabner et al., 2001), which drives further protein aggregation and oxidative 
damage to cells (Mao and Reddy, 2011). Mitochondria play a pivotal role in cell survival, but 
they are known to be a major source as well as a target for ROS (Trushina and McMurray, 














pathogenesis (Choi et al., 2014; Siskova et al., 2010; Wang et al., 2009), contributes to 
reduced ATP production, impaired Ca2+ buffering and continued generation of ROS (Beal, 
2007).  
A number of endogenous antioxidants protect cells from ROS-induced damage. Of these, 
superoxide dismutase (SOD), catalase (CAT), glutathione, and selenium (SE)-dependent 
glutathione peroxidase (GSHPx) have been well studied. The peroxiredoxins (Prdxs); of 
which there are six isoforms (Prdxs1-6), belong to a relatively new group of thiol-specific 
antioxidants (Fisher, 2011), that are divided into two categories, the 1-Cys and 2-Cys 
Prdxs, based on the number of cysteine (Cys) residues directly involved in the reduction of 
peroxides. Prdxs1-4 belong to the “typical” 2-Cys subgroup and have additional conserved 
Cys residues in the COOH-terminal region (Rhee et al., 2005). Prdx5 is the single 
representative of the “atypical” 2-Cys Prdx class in mammalians (Rhee et al., 2005), and 
the Prdx6 isoform has only the NH2-terminal-conserved Cys and is, therefore, classified as 
a 1-Cys Prdx (Fisher, 2011). Prdx6 uses glutathione and ascorbate as electron donors and 
is the only member of the Prdx family that has the ability to remove H2O2 and phospholipid 
hydroperoxides; therefore it is able to reduce the accumulation of phospholipid 
hydroperoxides in plasma membranes (Manevich et al., 2002). Astrocytes are the 
predominant source of brain Prdx6 (Asuni et al., 2014; Lafon-Cazal et al., 2003; Yang et al., 
2005), and its expression has been documented in several cell compartments, including the 
cytoplasm, secretory organelles, lysosomes and mitochondria (Eismann et al., 2009; 
Immenschuh and Baumgart-Vogt, 2005; Peshenko et al., 1998; Wu et al., 2006). It is also 
present in CSF, plasma and urine (Brown et al., 2013). 
Activation of antioxidant pathways is particularly important for tissue with relatively weak 
endogenous antioxidant defences, such as the brain. So, strict regulation of ROS is vital to 














reduction of cellular expression and activity of SOD, CAT, and GSHPx contribute to 
mechanisms of aging and neurodegenerative diseases such as AD and tauopathies 
(Calabrese et al., 2001; Dumont et al., 2011; Facecchia et al., 2011; Pamplona and 
Costantini, 2011). Oxidative stress generated early in disease pathogenesis likely 
overwhelms endogenous antioxidant defences, leading to exacerbation of pathology. In 
accord, progressive increase in intracellular ROS is associated with increased accumulation 
of protease resistant PrP (Haigh et al., 2011), which strengthens the direct mechanistic and 
pathogenic association between heightened ROS and on-going prion disease pathogenesis 
(Canello et al., 2010; Guentchev et al., 2000; Pamplona et al., 2008; Vassallo and Herms, 
2003; Wong et al., 2001). For this reason, up-regulation of ROS-detoxifying enzymes is 
thus a reasonable approach for amelioration of prion related pathology.  
In this study we focused our efforts on examining whether overexpression of the astrocyte-
specific antioxidant Prdx6 impacts prion-related neuropathology. We demonstrate 
biochemically that loss of Prdx6 protein exacerbates pathological indices of prion disease 
such as astrogliosis and accumulation of PK-resistant PrPSc. Genetic overexpression of 
Prdx6 augmented cognitive behaviour and attenuated prion-related astrocytosis. In addition 
to antibody-based treatment approaches, which modulate and/or remove abnormally 
misfolded protein aggregates (Pankiewicz et al., 2010; Sadowski et al., 2009), other 
strategies to protect cells at the mitochondrial level by stabilizing or restoring mitochondrial 
and redox function or by interfering with energy metabolism warrant attention. Our study 
supports the potential utility of targeted Prdx6 augmentation as a novel adjunct treatment 
for neurodegenerative diseases (Pak et al., 2011; Tulsawani et al., 2010), and 

















2. Experimental Procedures 
Ethics Statement: All procedures involving animals were approved by the Institutional 
Animal Care and Use Committee of the New York University and were performed in 
accordance with the U.K. Animals (Scientific Procedures) Act, 1986 and associated 
guidelines, the European Communities Council Directive of 24 November 1986 
(86/609/EEC) or the National Institutes of Health guide for the care and use of Laboratory 
animals (NIH Publications No. 80-23, revised 1978). All efforts were made to minimize 
animal suffering, and to reduce the number of animals used, and to utilize alternatives to in 
vivo techniques, if available. Animal Model: Age-matched nonTg C57BL6 mice (Control), 
transgenic Prdx6 knockout (KO) animals and Prdx6 (Tg) overexpressing animals were used 
in this study, and details regarding the generation of the knockout and transgenic animals 
have been described previously (Phelan et al., 2003; Wang et al., 2003). Cryopreserved 
embryos of stock #005974 and stock #005092 were purchased and re-derived at Jackson 
Laboratory to generate the initial cohort of homozygous females and males Prdx6 KO and 
Prdx6 Tg used in the study.  Mice were housed in a temperature- and humidity-controlled 
environment and had free access to food and water. 100 µl of 10% brain homogenate 
prepared from normal brains (NBH) or from terminally ill ME7-infected mice was injected 
intraperitoneal (i.p.) in cohorts of nonTg, Prdx6 KO and Prx6 Tg animals. Cohorts of n=12 
were set up, and all mice were 5-7 weeks old at the start of the study. ME7-infected mice 
were killed in early stages of symptomatic disease (<20 weeks post-injection), when a 
blinded observer scored the animal positive on the parallel bar for 3 consecutive weeks and 
robust neuroinvasion could be determined biochemically. At conclusion, the mice were 
terminated by terminal anaesthesia and the dates were noted. The mice were perfused with 
heparinized saline solution, and the brains portioned; with half formalin-fixed for 















2.1 Behavioural assessment 
Cognitive analysis of homozygous Prdx6 KO and Prdx6 Tg animals had not been 
previously reported; so for these studies we utilized the spontaneous novel object 
recognition (OR) test that requires little navigation, but is still able to measures deficits in 
short-term memory (Asuni et al., 2007). We reasoned that advanced prion disease related 
motor defects may not enable them to properly navigate the radial arm maze, which we 
have used extensively to assess the cognitive status of other models of neurodegeneration 
(Asuni et al., 2010a). OR testing was performed as we have previously described and as in 
those prior studies all objects tested were of equal inherent interest (Asuni et al., 2006). 
Following habituation and a trial phase normal mice remember a specific object over a 
delay up to 1 h and spend the majority of their time investigating the novel object during the 
retention trial. During retention tests, the animals were placed back into the same box, in 
which one of the previous familiar objects used during training was replaced by a second 
novel object, and allowed to explore freely for 6 min. The time spent exploring each object 
was recorded by an automatic tracking system (San Diego Instruments), and at the end of 
the training phase, the mouse was removed from the box for the duration of the retention 
delay (RD = 3 h). A different object pair was used for each trial for a given animal, and the 
order of exposure to object pairs as well as the designated sample and novel objects for 
each pair were counterbalanced within and across groups. The time spent exploring any 
one of the two objects (training session) is then compared to the novel one (retention 
session). 
We assessed the competency of mice to cross a series of parallel bars that are 3 mm in 
diameter and are placed 7 mm apart (Sadowski et al., 2003; Sadowski et al., 2009). The 
earliest detectable clinical symptoms of CNS involvement in prion disease include 
impairment in the level of activity and competency when the mouse attempts to cross the 














by a researcher blinded to the study constituents and an animal is considered clinically 
symptomatic if it scores positive for disease for three consecutive weeks, after which the 
animals are killed in accord with protocols approved by the New York University School of 
Medicine Institutional Animal Care and Use Committee. 
 
2.2 Neuropathological Examination of Brain Sections 
Coronal hippocampal sections were cut from formalin-fixed paraffin wax-embedded brains 
(10µm) or PLP fixed brains (40µm). As per our previous protocols the tissue were 
processed for immunohistology (Asuni et al., 2014; Asuni et al., 2010b). Briefly, selected 
sections were incubated in a humid chamber overnight at room temperature with specific 
antibodies. Negative control sections were covered with appropriate blocking serum while 
other sections were covered with primary antibody diluted in blocking buffer. Sections were 
scored for spongiosis, neuronal loss, gliosis, PrPSc deposition, and synaptophysin-signal 
intensity. Respectively, astrocytosis was detected using anti-glia fibrillary acidic protein 
(GFAP) polyclonal antiserum (DAKO; 1:2000 dilution), and synaptophysin was detected 
with Sy38 mAb (Abcam, 1:1000 dilution). Prdx6 staining was performed using rabbit anti-
Prdx6 mAb (Novus biologicals; 1:500 dilution). PrPSc in brain tissue was detected after 
denaturation of fixed sections in formic acid using 6D11 mAb to PrP as described (Asuni et 
al., 2014; Asuni et al., 2010b). Sections of brains from all animals killed at each time point 
and from those succumbing to scrapie were examined by the same person, blinded to the 
identity of the animal and time of killing.  
 
2.3 Semi-quantification of immunohistochemistry images 
The images were visualized on an 80i Nikon fluorescent microscope and were captured 
using a high-sensitivity, cooled, monochrome DS-Qi1Mc camera and NIS Elements 














of 600 dpi. All images were captured using identical exposure limit, gain, saturation, 
shading and filter. DAB staining within the images was identified using ImageJ v.1.42 
(National Institute of Mental Health, Bethesda, Maryland, USA; http://rsb.info.nih.gov/ij), 
with the Colour Deconvolution plugin to eliminate haematoxylin counterstain. Image 
threshold limit was lowered to a set level to remove background noise and kept constant for 
all images. Images were then converted to binary and the area of staining was measured 
with the “Analyze particles” routine (Schneider et al., 2012), and the percentage change in 
stained area was calculated with the nonTg C57BL6 animals serving as control. 
 
2.4 Primary Cultures  
Cortical neuronal cultures were prepared using neonatal 1 day old C57BL6, Prdx6 KO and 
Prdx6 Tg animals using a standard papain dissociation protocol (Worthington Biochemical 
Corporation, UK) and cultured in Neurobasal medium containing B27 supplement with 2 
mM glutamine, 50 U/ml penicillin and 50 µg/ml streptomycin (Invitrogen, USA). Cells were 
plated onto poly-l-lysine coated plates and allowed to differentiate for 7 days before use. 
Cortical astrocyte cultures were prepared using neonatal 1 day old C57BL6, Prdx6 KO and 
Prdx6 Tg animals as previously described (Le Roux and Reh, 1996), with modifications 
(Kuszczyk et al., 2013). Briefly, cerebral cortex was dissected out, trypsinized, and cells 
cultured in minimal essential medium (MEM) supplemented by 20% FBS (Hyclone, USA), 2 
mM glutamine, streptomycin (50 µg/ml) and penicillin (50 U/ml). After six days of growth the 
FBS content in MEM was decreased to 10%. Astrocytes were grown in 25 cm2 flasks until 
confluence. The purity of astrocytic cultures was >95% as assessed by GFAP 
immunostaining. Human neuroblastoma (SK-N-SH cell line # HTB-11) was obtained from 
the American Type Culture Collection (Manassas, VA) and cultured in minimal essential 














penicillin (100 units / mL) and streptomycin (100 µg / mL). All the cultures were maintained 
at 37°C in 5% CO 2 and 95% air. 
 
2.5 Biochemistry 
Extracted brains were lysed in a buffer composed of (50 mM Tris-HCl, pH 7.4, 150 mM 
NaCl, 1 mM ethylene glycol tetraacetic acid (EGTA), 1 mM Na3VO4, 1 mM NaF, 2.5 mM 
Na4P2O7, 1 mM β-glycerophosphate, 0.5% Triton, 0.5% sodium deoxycholate, 0.5 mM 
phenylmethylsulfonylfluoride (PMSF), protease inhibitor tablet (Roche, Indianapolis, IN, 
USA) or without PMSF for proteinase K (PK) digestion). To assess PK-resistant conformers 
of PrP, brain homogenates were treated with PK (1µg/µL) 1:20 dilution at 37°C for 1 h, 
according to previous methods (Pankiewicz et al., 2006; Perrier et al., 2004). After 
incubation, digestion is stopped by the addition of PMSF to 4 mM. Samples were then 
centrifuged at 20 000 g for 45 min at 4°C. Pellets were resuspended in 15 µL Tris-buffered 
saline and 15 µL sample buffer, boiled for 5 min and then resolved on SDS-PAGE gels as 
described previously (Jimenez-Huete et al., 1998). Homogenates were separated by SDS-
PAGE and membranes were incubated with the desired primary antibodies overnight at 
4°C. All antibodies were used at the manufacturers recommended dilutions and included 
anti-synaptophysin, GFAP, PSD-95 (all Abcam), Prdx6 (Novus biologicals) and anti-PrP 
6D11 mAb (kind gift of Kascsak, RJ (Spinner et al., 2007)). In past studies following 
incubating of homogenates with or without PK in order to destroy the PrPc, and retain 
proteinase K-resistant fragments (PrPSc) it was demonstrated that an increase in PrP 
immunoreactivity in disease animals relates to an increasing deposition and accumulation 
of PrPSc fragments. Hence increased anti-PrP mAb immunoreactivity is considered 
representative of increasing accumulation of PrPSc (Asuni et al., 2014; Asuni et al., 2010a; 
Gray et al., 2009). The antigen-antibody complexes were detected using horseradish 














and visualized using SuperSignal; Pierce Chemical (Rockford, IL). The exposure time was 
kept standard for all experiments at 1 min. Developed films were converted into eight-bit 
grayscale digital files using a Epson Perfection 4990 scanner (Epson America, Long Beach, 
CA, USA) and Adobe Photoshop software 7.01 (Adobe Systems, San Jose, CA, USA) and 
saved in a TIF format with a resolution of 600 dpi. Quantification of protein bands were 
performed by densitometric analysis of the films using NIH Image J software v. 1.42.  
 
2.6 Protein purification. 
The pTAT-Prdx6 construct was generated by inserting the coding region of the human 
Prdx6 in the EcoR1/BamH1 sites of a pET-28b-TAT (V2.1) expression vector (kindly 
provided by Stephen Dowdy, University of California San Diego, San Diego, CA)(Becker-
Hapak et al., 2001)	 in frame with the TAT/protein transduction domain peptide 
(YGRKKRRQRRR) (Vocero-Akbani et al., 1999). The Prdx6 cDNA inserted into the pTAT 
vector was generated by PCR amplification of the human cDNA.  The oligonucleotides 
AGG ATC CAT GCC CGG AGG TCT GC and AGA ATT CTT AAG GCT GGG GT were 
used as forward and reverse primers, respectively. pTAT-Prdx6 and pTAT plasmids were 
transformed into the Escherichia coli strain BL21(DE3), bacterial cultures were grown 
overnight, and protein expressions were induced by (isopropyl β-D-1 
thiogalactopyranoside) treatment for 5-6 h followed by sonication in a buffer solution 
containing 300 mM NaCl, 10 mM Tris·HCl, 20 mM imidazole, and 8 M urea, pH 8.0 (binding 
buffer) in the presence of protease inhibitor cocktail (Roche). The His-tagged fusion 
proteins were purified using Ni2+-nitrilotriacetic acid-agarose affinity column (Invitrogen, 
Carlsbad, CA) through a sequential wash with buffer containing 300 mM NaCl, 10 mM 
Tris·HCl, 50 mM imidazole, and 8 M urea, pH 8, followed by elution with a buffer containing 
300 mM NaCl, 10 mM Tris·HCl, 200 mM imidazole, and 8 M urea, pH 8.0. The elutate was 














TAT-fusion proteins were then desalted on a PD-10 column (GE Healthcare, Piscataway, 
NJ) into phosphate-buffered saline (PBS) for use. 
 
2.7 Measurement of cell viability 
Cell viability was determined by the MTT assay (Roche Diagnosis, Indianapolis, IN) as 
previously described (Sadowski et al., 2009). Briefly, SK-N-SH human neuroblastoma cells 
were seeded in at 104 cells/well in 96-well plates (100 µl total culture volume). Cells were 
exposed to 2.5 mM H2O2 or 50 µM CoCl2 in the absence or presence of recombinant 
Prdx6-TAT protein (5ug/ml). 48 h after treatment, cell viability was determined. The 
absorbance of the solubilized MTT product was measured at 590 nm using the absorbance 
of cell-free wells for background subtraction. The proportion of apoptotic nuclei were 
assessed following chromatin staining with Hoechst 33258, and defined as the presence of 
two or more condensed bodies per nucleus counted. Prdx6 induced protection of the CoCl2-
induced cytotoxicity in astrocytes was also assessed using the MTT assay as detailed 
above. 
 
2.8 Real-time semiquantitative RT-PCR (qRT-PCR). 
Prdx6 mRNA expression was quantified by quantitative PCR (qRT-PCR), and the relative 
expression ratio was calculated based on the 2-∆∆CT method (Livak and Schmittgen, 
2001). RNA was isolated using RNAeasy kit (Qiagen) and cDNA was synthesized from 500 
ng of total RNA using an iScript cDNA synthesis kit (BioRad). qPCR was performed on a 
Bio-Rad iCycler detection system in triplicate using SYBR Green (BioRad) with Prdx6 and 
β-actin primers which were designed using Primer Express software (Applied Biosystems, 
Paisley, UK) and purchased from Sigma Genosys. Primers were as follows: β-actin 
forward: 5’CTA AGG CCA ACC GTG AAA AG 3’ and reverse: 5’ACC AGA GGC ATA CAG 














5'GGG AAC TAC CAT CAC GCT CT 3’. Cycling parameters: an initial single step at 95 °C 
for 10 min (denaturation) followed by 40 cycles of 94 °C for 30 s (denaturation), 60 °C for 
45 s (annealing), and 72 °C for 30 s (elongation). A final elongation/termination step was 
performed at 72 °C for 10 min. Using the average cy cle threshold (CT) calculated from 
multiple measurements. Mean relative expression of Prdx6 from three independent 
experiments (different experimental replicates) are reported normalized to control Actin. 
 
2.9 Statistical analyses 
All data are expressed as mean ± SEM unless otherwise stated. Individual data sets were 
tested for normality using the Shapiro-Wilk and D'Agostino & Pearson omnibus normality 
test. Student's t tests were applied to all data sets with two tails (two samples; unequal 
variance), and Mann Whitney U tests (Wilcoxon rank sum tests) were performed where 
data was not normally distributed. Overall, significance of differences between NBH and 
ME7 animals across the different strains was determined by one-way ANOVA followed by 
the post hoc test. Values of p<0.05 were considered to be statistically significant. 
Densitometric data in each bar represents means ± SEM, and One-way ANOVA -test was 
applied to biochemical data with a direct comparison between the nonTg and other strains. 
For behavioural measures, two-way ANOVA for repeated measures was used with time as 
the within-subject factors and NBH or ME7 infection treatment as the between-subject 
factors, followed by Bonferroni’s post hoc tests. Two-way ANOVA was used to compare 
strain differences in ME7-animals. At conclusion, the termination dates of the mice were 
plotted on a Kaplan-Meier survival curve to demonstrate what effect the presence or 
absence of Prdx6 has on the different groups. Survival analysis by log-rank (Mantel-Cox) 
test gave a p<0.001 for ME7 Prdx6 Tg compared to ME7 Prdx6 KO animals. The median 
survival for ME7 Prdx6 KO animals was 185 dpi, and 195 dpi for ME7 Prdx6 Tg, compared 














points. Overall this represents a prolongation of the asymptomatic incubation of 10% 
compared to controls, respectively. None of the control animals showed signs of cerebellar 
ataxia through 216 days, which represented 2 weeks of continuous monitoring. All statistical 
analyses were made using Graph Pad Prism 6.0 (Graph Pad Software Inc., San Diego, CA, 
USA). 
3. Results 
3.1 Exogenous TAT-Prdx6 attenuates ER and oxidative stress. 
ER and oxidative stress are coupled to disruption of protein folding (Malhotra and 
Kaufman, 2011), and genetic or chemical intervention to reduce ROS species improves 
protein folding and cell survival and may provide an avenue to treat and/or prevent 
diseases of protein misfolding (Fatma et al., 2008; Malhotra et al., 2008). We examined 
whether exogenous Prdx6 would rescues chemically induced oxidative stress (H2O2)  o r  
c e l l u l a r  h yp o x ia  ( CoCl2) in SK-N-SH human neuroblastoma cells. The capacity of the 
cells to reduce MTT was used as a measure of cell viability, and the results are presented 
as the percentage of the absorbance determined for control conditions (DMSO only) and 
represent the means ± SEM of duplicate experiments. As shown in (Figure 1), cell viability 
decreased significantly following 2.5mM H2O2 evoked oxidative stress, with only 45% of the 
cells surviving 48 h of cultivation, while over 60% survived in the presence of exogenous 
5ug/ml TAT-Prdx6 (Figure 1A, p<0.0001). Similarly, the viability of the cells was decreased 
significantly to about 40% in the presence of 50uM CoCl2 after 48 h (Figure 1A), and there 
was a rescue to about 65% in the presence of 5ug/ml exogenous TAT-Prdx6 (Figure 1A, 
p<0.0001). This is consistent with past reports showing the ability of TAT-Prdx6 to rescue 
cytotoxicity (Kubo et al., 2009; Wang et al., 2006). The dose used in this study was chosen 














(Fatma et al., 2008; Fatma et al., 2009). They also demonstrate transduction of TAT-Prdx6 
into cells (Kubo et al., 2008).  
 
We observed that cellular damage induced by CoCl2 in wild-type primary cortical neuron 
cells was attenuated by treatment with exogenous TAT-Prdx6 (Figure 1B, left panel), and 
by semi-quantitative analysis using Hoechst staining we show that CoCl2-induced apoptosis 
was significantly decreased by treatment with 5ug/ml TAT-Prdx6 (Figure 1B, right panel). 
The decreases in percentages of apoptotic cells were from 40.67% in CoCl2-treated cells to 
19.83% in TAT-Prdx6-treated cells (p<0.0001) (Figure 1C). We extracted primary 
astrocytes from nonTg, Prdx6 KO and Prdx6 Tg animals (Figure 1D, 1E and 1F), and 
demonstrated a concentration dependent increase in CoCl2 toxicity in all the strains. 
However, there were clear differences in how the cultures behaved. For example, following 
treatment with 1 mM CoCl2, the deleterious metabolic activity was more marked in Prdx6 
KO astrocytes (Figure 1D) which showed a 28.77% decrease in viability whereas both 
nonTg and Prdx6 Tg astrocytes (Figure 1E and 1F) only showed a 16.78% and 14.98% 
decrease in viability, respectively, consistent with a protective role for Prdx6 expression. 
These data supports the notion that overexpression of Prdx6 could attenuate 
neurodegeneration. So working on the hypothesis that a feasible mechanism for modulating 
cellular stress may be to up-regulate endogenous ROS-detoxifying enzymes, we set out to 
explore whether transgenic overexpressing of antioxidant Prdx6 in mice was sufficient to 
attenuate neurodegeneration initiated by accumulation of misfolded PrPSc in prion disease.  
 
3.2 Characterization of Prdx6 animals  
Initial studies were carried out to confirm and characterize the expression of Prdx6 in the 
brains of homozygous Prdx6 Tg animals and its absence in homozygous Prdx6 KO 














express detectable Prdx6, whereas in primary astrocytes and brain homogenates from 
Prdx6 Tg and nonTg animals there was expression of Prdx6 compared to Prdx6 KO 
animals (Figure 2A). There was a significant 15.22-fold increase in Prdx6 protein levels in 
astrocytes from Prdx6 Tg mice when compared nonTg animals (p<0.001) (data not shown), 
and we observed an equally marked 4.48-fold increase in Prdx6 protein expression in 
whole brain homogenates from Prdx6 Tg mice when compared with the nonTg animals 
(p<0.001) (data not shown). This is consistent with prior described astrocytic expression of 
Prdx6, and supported by Prdx6 mRNA analysis showing that the brains of Prdx6 Tg mice 
exhibit an approximately 15-fold increase in Prdx6 mRNA compared with the nonTg 
animals (Figure 2B, p<0.001) while there was no expression of Prdx6 mRNA in Prdx6 KO 
animals compared to nonTg animals (Figure 2B, p<0.001). Prdx6 has previously been 
characterized in C57BL6 mouse by in situ hybridization, and was demonstrated to be 
expressed in discrete regions of the brain including the cortex and hippocampus (Figure 
2C). We examined the brain expression pattern of Prdx6 in nonTg, Prdx6 KO and Prdx6 Tg 
animals by immunohistology. As expected, there was no expression of Prdx6 in Prdx6 KO 
animals (Figure 2D, middle panel), and there was some staining in nonTg animals (left side 
panel), in contrast to the robust staining we observed in Prdx6 Tg animals (Figure 2D, right 
side panel). Prdx6 immunoreactivity (IR) in Prdx6 Tg animals is distributed around the brain 
in a mosaic pattern and appears to decorate astrocyte-like structures, consistent with 
astrocytes being the predominant source of brain Prdx6. The Prdx6 IR in some cells 
decorates the neuropil reminiscent of dye-filled astrocytes with fine processes.  
 
3.3 Behavioural changes in Prdx6 KO and Prdx6 Tg animals 
Prior to initiating prion pathology Prdx6 KO and Prdx6 Tg animals were weighed to 
determine if there were any atypical transgene-associated differences, and we did not 














animals weighed 21.88±0.31g respectively. Cohorts of animals were inoculated with normal 
brain homogenate (NBH), and pathological ME7 strain of prion, and were monitored 
biweekly and their weights measured, and we saw no differences in the course of this study 
(Figure 3A). Based on our prior experience we anticipated these animals would begin to 
show obvious pathology after 150 days post inoculation (dpi), and monitored them more 
closely once this time had elapsed. Using our established protocols mice were subjected to 
weekly behavioural testing on traverse parallel bars to monitor clinical signs of prion 
infection using a test of motor co-ordination for three consecutive weeks by an observer 
blinded to the experimental status of the animals (data not shown). Animals were sacrificed 
after 3 weeks of positive scoring. Differences in Kaplan-Meier survival curves of nonTg 
NBH, nonTg ME7, Prdx6 KO NBH, Prdx6 KO ME7, Prdx6 Tg NBH and Prdx6 Tg ME7 were 
analyzed by the Log-rank test (Figure 3B). Kaplan-Meier survival curves revealed that loss 
of Prdx6 in Prdx6 KO ME7-animals significantly worsened survival compared to Prdx6 
expression in Prdx6 Tg ME7-animals which extended median survival by 10 days (Figure 
3B). Prdx6 KO ME7 compared to Prdx6 Tg ME7 p<0.0004 (Mantel-cox) (Figure 3B), but 
nonTg ME7 were not significantly different from Prdx6 Tg ME7 (p=0.0918). These animals 
were also subjected to a novel object recognition task, which revealed that both nonTg 
ME7-animals and nonTg NBH-animals could discriminate novel from old objects (Figure 
3C, p=0.011 and p=0.026, respectively), but there was no difference in their ability to 
discriminate novel objects (p=0.714). Prdx6 KO NBH-animal could significantly discriminate 
novel from old objects (Figure 3D, p=0.0013), whereas Prdx6 KO ME7-animals could not 
(p=0.402), and Prdx6 KO NBH-animal spent significantly more time with the novel objects 
than Prdx6 KO ME7-animals (p=0.0008). Conversely both Prdx6 Tg ME7-animals and 
Prdx6 Tg NBH-animals could discriminate novel from old objects (Figure 3E, p=0.0001 and 














novel object than Prdx6 ME7-animals (p<0.0001). Prdx6 KO ME7-animals spent the least 
time with the novel objects, in contrast to nonTg ME7- and Prdx6 Tg ME7-animals (Figure 
3F, 37.8% compared to 55.7%, and 55.8% for nonTg and Prdx6 Tg respectively). 
Furthermore, all cohorts of NBH-animals were able to discriminate novel objects, but Prdx6 
Tg NBH-animals showed the most preference for the novel objects (Figure 3G, 80.56% 
compared to 62%, and 59% for non Tg and Prdx6 KO, respectively). 
 
3.4 Altered prion-related pathology in Prdx6 KO and Prdx6 Tg animals 
To determine whether the altered behaviour effect observed in Prdx6 Tg ME7-animals 
translated into pronounced changes in biochemical correlates of prion pathology, animals 
were sacrificed in early stages of symptomatic disease (after 3 weeks of positive scoring) 
when there was significant accumulation of misfolded PrPSc and no overt neuronal loss. We 
measured the extent of pathology by quantitative biochemical estimates of protein changes 
in brain extracts from control, and ME7-animals. We observed a significant increase in PrP 
(PrPc/PrPSc) immunoreactivity (IR) in nonTg- , Prdx6 KO- and Prdx6 Tg-ME7 compared to 
NBH-animals at the same time point (Figure 4A, panel i; Figure 4B, graph i). 
Concomitantly there was significantly less accumulated PK resistant PrPSc in Prdx6 Tg 
ME7-animals compared to Prdx6 KO-ME7-animals (Figure 4A, panel ii; Figure 4B, graph 
ii; p<0.05), but there was no significant difference in the PrPSc IR in nonTg-ME7 compared 
to Prdx6 KO-ME7. NonTg NBH-animals expressed Prdx6 protein, but there was additional 
induction in nonTg ME7-animals (Figure 4A, panel iii; Figure 4B, graph iii; p<0.05). As 
anticipated there was no Prdx6 expression in the cohorts of Prdx6 KO animals used 
(Figure 4A and Figure 4B, graph iii). There was robust expression of Prdx6 protein in both 
Prdx6 Tg NBH- and Prdx6 Tg ME7-animals but the levels were not significantly different 
(Figure 4A and Figure 4B, panel iii), but the levels were significantly different from 














neuropathology, GFAP IR was significantly increased in all ME7-animals, but there was 
significantly less in Prdx6 Tg ME7-animals compared Prdx6 KO ME7-animals (Figure 4A, 
panel iv; Figure 4B, graph iv; p<0.001), as a muted ME7 pathology was generated in Prdx6 
Tg animals. Synaptophysin immunoreactivity was not markedly decreased in either cohort 
of animals (Figure 4A, panel v; Figure 4B, graph v), and there was no change in the 
expression of (post synaptic density protein) PSD-95 in nonTg, Prdx6 KO and Prdx6 Tg 
ME7 compared to NBH-animals (not shown).  
We examined prion-related gliosis and synaptopathy by DAB immunostaining and semi-
quantitatively measured the difference in DAB intensity in the hippocampus of both the 
Prdx6 Tg and Prdx6 KO ME7-animals and expressed this as a percent immunoreactivity 
relative to similarly stained sections from nonTg ME7-animals. We show that there was 
markedly increased GFAP IR in the hippocampus of nonTg ME7- and Prdx6 KO ME7-
animals, which was significantly different from that in Prdx6 Tg ME7-animals (Figure 5A-D, 
p<0.05 respectively). In nonTg ME7- and Prdx6 KO ME7-animals hippocampal 
synaptophysin staining was significantly decreased compared to Prdx6 Tg ME7-animals, 
(Figure 5E-H, p<0.05 and p<0.001 respectively), but more indicative of this is the loss of 
demarcated synaptic layers and increasing disorganisation of synaptic architecture 




4.1 Prdx6 is cytoprotective against chemically induced oxidative stress and 
hypoxia 
To demonstrate Prdx6 mediated antioxidant capacity, we examined whether exogenous 
Prdx6 would rescue chemically evoked oxidative stress and activation of mitochondrial-














that cell viability decreased significantly in the presence of 2.5 mM H2O2, with only 45% of 
the cells surviving 48 h of cultivation, while over 60% survived in the presence of 
exogenous TAT-Prdx6. We also observed that the viability of SK-N-SH human 
neuroblastoma cells was significantly decreased by about 40% in the presence of 50uM 
CoCl2 after 48 h, and once again it was rescued with an application of exogenous TAT-
Prdx6. This is consistent with past results showing the ability of Prdx6 to rescue cytotoxicity 
(Kubo et al., 2009; Tulsawani et al., 2010; Wang et al., 2006). Semi-quantitative analysis 
using Hoechst staining showed that CoCl2-induced apoptosis was significantly decreased 
by treatment with TAT-Prdx6. The decreases in percentages of apoptotic cells were from 
41% in CoCl2-treated cells to approximately 20% in Prdx6-treated cells (p<0.0001). The 
altered neuronal homeostasis and synaptic integrity represented by dendritic dystrophy we 
observed in CoCl2 cortical neurons is in contrast to the intact complex dendritic network 
with smooth and long dendritic arborization visible in 5ug/ml TAT-Prdx6 augmented cells. 
So given the cytoprotective effect of Prdx6 on H2O2 a n d  CoCl2 treated neuroblastoma 
cells we postulated that Prdx6 could metabolize peroxides generated as a consequence of 
prion induced oxidative stress, thus protecting cells as prion-related neuropathology 
ensues.  
4.2 Redox dysfunction in chronic degenerative disorders. 
Strict regulation of ROS is vital to maintain cellular integrity and homeostasis, and activation 
of antioxidant pathways are particularly important for the brain with relatively weak 
endogenous antioxidant defences. So unsurprisingly, reduction of cellular expression and 
activity of antioxidant proteins are known corollary of aging and neurodegenerative 
diseases (Calabrese et al., 2001; Dumont et al., 2011; Pamplona and Costantini, 2011). 
This oxidative stress is be the consequence of an increased production of reactive species, 
a decrease in the capacity of antioxidant defenses to remove them, or both. In prion 














levels of peroxynitrite, which can then cause damage through the formation of hydroxyl 
radicals or via nitration of tyrosine residues on proteins (Guentchev et al., 2000). We 
previously demonstrated a significant upregulation of Clusterin, GFAP, EAAT-2 and Prdx6 
in ME7- compared to NBH-animals (Asuni et al., 2014). Primarily this increase in astrocyte-
expressed proteins reinforced the notion that astrocytes are significant contributors to 
disease mechanisms (Gray et al., 2006; Lazarini et al., 1994), but we also considered that 
increased expression of antioxidant Prdx6 represents a physiological response initiated to 
modulate the redox dysfunction and associated neurodegeneration initiated by misfolded 
PrPSc. This lead us to explore whether transgenic overexpressing of antioxidant Prdx6 in 
mice was sufficient to attenuate neurodegeneration initiated by accumulation of misfolded 
PrPSc in prion disease.  
 
4.3 Prdx6 attenuates prion-related pathology in vivo 
We showed that Prdx6 expression was predominant in astrocytes of nonTg, and Prdx6 Tg 
animals, with no expression in Prdx6 KO animals. The animals were then inoculated with 
either NBH or pathological ME7 strain of prion. At the first evidence that these animals 
scored positive for scrapie for 3 weeks, we subjected the animals to a mild cognitive test. 
Both nonTg and Prdx6 Tg NBH- and ME7-aniamls could clearly discriminate novel from old 
objects, but compared to Prdx6 KO NBH-animals, Prdx6 KO ME7-animals showed 
significant reduction in their ability to discriminate novel from old objects, which we interpret 
to mean that prion-induced neuropathology more adversely impacted mild cognition in 
these animals. Interestingly Prdx6 Tg NBH-animals also spent significantly more time with 
the novel object than nonTg NBH-animals which suggests added Prdx6 augmentation of 
their ability to discriminate novel objects. Remarkably, based on time of sacrifice post-
disease onset Kaplan-Meier survival curves were generated which showed a significant 10 














compared to Prdx6 KO ME7-animals (p<0.05). There was also a difference compared the 
nonTg ME7-aniamls which was not significant.  
 
Our biochemical analyses reveal significant increase in PrP load in ME7- compared to 
NBH-animals, but there was demonstrably more PrP load in Prdx6 KO ME7- compared to 
Prdx6 Tg ME7-animals. Proteinase K digestion liberated pathological PrPSc in the brains of 
these animals, and there was a significant decrease in pathological PrPSc in Prdx6 Tg ME7- 
compared to Prdx6 KO ME7-animals. Our biochemical data also showed significantly less 
astrocytosis in Prdx6 Tg ME7- compared to Prdx6 KO ME7- and nonTg ME7-animals; but 
synaptophysin immunoreactivity was not markedly different when quantified by western 
blotting. This is likely because whole brain homogenates were utilised for this measure. 
Consistent with the remaining biochemical data, our histological analysis revealed less 
astrocytosis in Prdx6 Tg ME7- compared to Prdx6 KO ME7- and nonTg ME7-animals; and 
shows a pronounced loss of synaptophysin immunoreactivity, and synaptic demarcation. 
Our results demonstrate that lack of Prdx6 negatively impacts prion-related neuropathology 
and associated behaviour, and confirmed that the presence of antioxidant Prdx6 attenuates 
prion-related neuropathology. Gene expression of Peroxiredoxin 1-5, glutaredoxin 1-4, 
catalases, superoxide dismutases 1-3, thioredoxin 1-2, and glutathione peroxidases 1-2 
antioxidant is not different between Prdx6 KO and control animals (Wang et al., 2003), 
suggesting that the Prdx6 antioxidant properties in these mice was independent of other 
antioxidant enzymes. 
NonTg NBH-animals expressed Prdx6 protein, but there was additional induction in nonTg 
ME7-animals, suggestive of its protective induction in response to the accumulation of 
PrPSc. In accord nonTg ME7- compared to nonTg NBH-animals, both Prdx-6 and PrP 














expression of these proteins is due solely to post-translational modification, mediated by the 
increasing accumulation of misfolded protein. We would hypothesize that as a result of 
increased Prdx6 expression, mitochondria from Prdx6 Tg mice may produce significantly 
reduced amount of H2O2, and cells from Prdx6 Tg mice could have increased resistance to 
stress-induced cell death and apoptosis. A balance between the pro-oxidant and anti-
oxidant levels exists under physiological conditions; however, other factors or disease 
cause an imbalance leading to increased production of stressors like ROS. Increased ROS 
perpetuates the degenerative cascade, by increasing production of toxic lipid peroxidation 
products, which further contributes to oxidative stress-induced cell death. Others have 
documented increased levels of lipid peroxidation in prion disease (Brazier et al., 2006). 
 
There is indeed prior precedent for astrocyte-mediated neuroprotection in 
neurodegenerative disease (Shao et al., 2012; Yata et al., 2011), and in this study we 
observed significant protective effects of exogenous TAT-Prdx6 in acute in vitro systems, 
and we show that expression of astrocyte-specific antioxidant protein Prdx6 in Prdx6 Tg 
ME7-animals reduced severity of the clinical abnormalities, improved neuropathology and 
increased survival time compared to Prdx6 KO ME7-animals. Over time prion disease 
mediates chronic, low-levels of oxidative stress, likely overwhelming protective responses 
and altering cellular homeostasis, therefore dramatic protective effects are not evident in 
the Prdx6 ME7- compared to Prdx6 KO ME7- or nonTg ME7-animals.  
 
Knockdown of Prdx6 resulted in increased sensitivity to oxidative injury (Manevich et al., 
2002; Pak et al., 2002), similar to observations made in Prdx6 null animals (Wang et al., 
2003). SOD1, another endogenous antioxidant has also been shown to attenuate prion-
related pathology (Akhtar et al., 2013). Our rationale for pursuing Prdx6’s protective effect is 














the accumulation of specific misfolded proteins (prion or Aβ or α-synuclein) significantly 
contributes to disease pathogenesis (Bredesen, 2008; Hara and Snyder, 2007; Siskova et 
al., 2010), and a desirable therapeutic approach would be one designed to upregulate 
astrocytic neuroprotective capacity without inducing inflammatory cytokines. Based on 
these data, we propose a redox modulator role for Prdx-6 in regulating and maintaining 
cellular homeostasis via its ability to control the ROS levels and suppress the activation of 
detrimental signalling pathways. Despite abundant evidence of a significant role for oxidant 
in the CNS degeneration, only few oxidant protective approaches have been employed, 
with inconclusive results and very limited success (Adair et al., 2001; Galasko et al., 2012; 
Hager et al., 2007; Markesbery, 1999; Subbarao et al., 1990). We are encouraged by a 
recent study which shows Prdx6-mediated protection against Aβ pathology in vitro (Kim et 
al., 2013). TAT-Prdx-6 has been shown to attenuate neurotoxicity in vitro, and may similarly 
have potential to prevent degeneration in vivo (Kubo et al., 2008). We believe augmentation 
of endogenous Prdx6 protein represents an attractive adjunct therapeutic approach for 
neurodegenerative diseases, and these findings provide a foundation for rational 
development of antioxidant-based therapeutics for acute and chronic degenerative 
diseases.   
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Figure 1. (A) MTT assay showing that TAT-Prdx6 (5ug/ml) attenuates H2O2 and CoCl2 
mediated cytotoxicity in SK-N-SH human neuroblastoma cells. Cells were cultured and 
treated for 48 h with indicated concentrations of H2O2 and CoCl2. The capacity of the cells 
to reduce MTT was used as a measure of cell viability, and the results are presented as the 
percentage of the absorbance estimated when compared with the control cells treated with 
DMSO only. Each bar represents a mean ± SEM. (B Top panel, and C): Photomicrograph 
of primary cortical neurons with or without CoCl2 treatment, showing significant cell death in 
control (left side) compared to exogenous TAT-Prdx6 (5ug/ml) supplemented cells (right 
side). (B Bottom panel, and C): Cortical neurons exposed to CoCl2 (left side) displayed 
significantly more evidence of apoptosis as evaluated by Hoechst stain for condensed 
nuclei compared to untreated control cells; in contrast to exogenous TAT-Prdx6 (5ug/ml) 
supplemented cells (right side, p<0.0001 and p<0.001 respectively). Arrows denote beading 
and dead cells. (D, E and F) There was concentration dependent increase in CoCl2 toxicity 
in astrocytes from nonTg, Prdx6 KO and Prdx6 Tg animals. The capacity of the cells to 
reduce MTT was used as a measure of cell viability, and the results are presented as the 
percentage of the absorbance determined for control conditions (DMSO only) and represent 
the means ± SEM of at least three independent experiments performed in duplicate. The 
deleterious metabolic activity was more marked in Prdx6 KO astrocytes compared to both 
nonTg and Prdx6 Tg astrocytes.  
Figure 2. Prdx6 expression in nonTg, Prdx6 Tg and Prdx6 KO animals. (A) Western blot 
analysis to confirm Prdx6 expression. Primary neurons, primary astrocytes and brain 
homogenates from naïve wild type nonTg, Prdx6 Tg and Prdx6 KO animals were probed for 
the presence of Prdx6 (Prdx6 mAb). Representative blots from 3 sets of experiments. Lane 
1-3; nonTg, Prdx6 Tg, Prdx6 KO (neurons), lanes 4-6; nonTg, Prdx6 Tg, Prdx6 KO 
(astrocytes), lanes 7-9; nonTg, Prdx6 Tg, Prdx6 KO brain homogenates. There was no 
Prdx6 protein detected in either neurons, astrocytes or brain homogenates from Prdx6 KO 
animals, but we observed a significant 15.22-fold increase in Prdx6 protein levels in 
astrocytes from Prdx6 Tg mice when compared with the nonTg animals (p<0.001) (data not 
shown). We observed an equally marked 4.48-fold increase in Prdx6 protein expression in 
whole brain homogenates from Prdx6 Tg mice when compared with the nonTg animals 
(p<0.001) (data not shown). (B) The brains of Prdx6 Tg mice exhibit an approximately 15-














no expression of Prdx6 mRNA in Prdx6 KO animals compared to nonTg animals (p<0.001). 
Data in graphs are presented as means ± SEM of at least three independent experiments. 
(C) Prdx6 has previously been characterized in nonTg mice by in situ hybridization (upper 
panel), where it is shown to be expressed in discrete regions of the brain including the 
cortex and hippocampus (lower panel). Shown in sagittal plane is the expression pattern of 
Prdx6 in the brain of a nonTg mouse. Probe Prdx6 - RP_040916_01_A07 - sagittal. 
NM_007453.2 Image credit: Allen Institute for Brain Science (Lein et al., 2007). (D) 
Immunohistological analysis of nonTg (left panel), and Prdx6 Tg animals (right panel) 
revealed marked Prdx6 IR but there was no Prdx6 IR in Prdx6 KO animals (middle panel). 
20x mag, and scale bar is 100 µm.  
  
Figure 3. (A) Cohorts of n = 12 were set up for the study. Animals were weighed monthly to 
determine if there were any atypical changes prior to eventual clinical disease onset. In the 
course of the study there were no significant differences in the weights of the animals. 
Prdx6 Tg animals weighed 22.16±0.28g, while Prdx6 KO animals weighed 21.88±0.31g 
respectively. (B) Shows prolonged survival in Prdx6 Tg animals with established prion 
disease. Starting at 120 dpi both NBH- and ME7-animals were tested weekly for signs of 
ataxia, characteristic of neuroinvasion and disease onset. Animals were sacrificed after 3 
weeks of positive scoring. Differences in Kaplan-Meier survival curves of NBH and ME7 
(nonTg, Prdx6 KO and Prdx6 Tg) were analyzed by the Log-rank test. All NBH and ME7 
plots were significantly different (p<0.0001). Although nonTg ME7 compared to Prdx6 Tg 
ME7 was not significantly different (Mantel-Cox=2.842, df=1, p=0.0918, hazard ratio (HR) = 
1.757), nonTg ME7 compared to Prdx6 KO ME7 was significantly different (Mantel-
Cox=7.58, df=1, p<0.0059, hazard ratio (HR) = 0.39). Prdx6 KO ME7 compared to Prdx6 
Tg ME7 was also significantly different (Mantel-Cox=12.70, df=1, p<0.0004, hazard ratio 
(HR) = 3.41). Prdx6 KO ME7 animals died within 150-185 dpi, while nonTg ME7 and Prdx6 
Tg ME7 animals survived longer, living up to 192 and 195 dpi, respectively. The healthy 
NBH-animals were killed after 216 days. (C) Prior to sacrificing, mice underwent a mild 
cognitive test (novel object recognition task). Both nonTg ME7-animals and nonTg NBH-
animals could discriminate novel from old objects (p=0.011 and p=0.026, respectively) and 
there was no difference in their ability to discriminate novel objects (p=0.714). (D) Prdx6 KO 
NBH-animal could significantly discriminate novel from old objects (p=0.0013), whereas 
Prdx6 KO ME7-animals could not (p=0.402), and Prdx6 KO NBH-animal spent significantly 














(E) Both Prdx6 Tg ME7-animals and Prdx6 Tg NBH-animals could discriminate novel from 
old objects (p=0.0001 and p=0.0042, respectively) but Prdx6 Tg NBH-animals spent 
significantly more time with the novel object than Prdx6 ME7-animals (p<0.0001). (F) ME7 
Prdx6 KO animals spent the least time with the novel objects, in contrast to nonTg ME7 and 
Prdx6 Tg ME7-animals (37.8% compared to 55.7%, and 55.8% for nonTg and Prdx6 Tg 
respectively). (G) Although all cohorts of NBH-animals were able to discriminate novel 
objects, Prdx6 Tg NBH-animals showed the most preference for the novel objects (80.56% 
compared to 62%, and 59% for non Tg and Prdx6 KO respectively). 
 
Figure 4. Representative western blots showing change in prion related biochemistry 
representative of n=6 per group. We observed a significant increase in PrP 
immunoreactivity (IR) (PrPC/PrPSc) as detected by anti-PrP 6D11 mAb in nonTg, Prdx6 KO 
and Prdx6 Tg-ME7 compared to NBH-animals at the time point analysed (A; panel i and B; 
graph i). There was significantly less accumulated PK resistant PrPSc in Prdx6 Tg ME7-
animals compared to Prdx6 KO-ME7-animals (A, panel ii; B, graph ii; p<0.05), but there 
was no significant difference in the PrPSc IR in nonTg-ME7 compared to Prdx6 KO-ME7.  
There was no Prdx6 expression in the cohorts of Prdx6 KO animals used (A, panel iii; B, 
graph iii). There was robust expression of Prdx6 protein in both Prdx6 Tg NBH- and Prdx6 
Tg ME7-animals but the levels were not significantly different (A, panel iii; B, graph iii;), but 
the levels were significantly different from expression in nonTg animals (p<0.001, 
respectively).  
GFAP IR was significantly increased in all ME7-animals, but there was significantly less in 
Prdx6 Tg ME7-animals compared Prdx6 KO ME7-animals (A, panel iv; B, graph iv; 
p<0.001).  
Synaptophysin was not markedly decreased in either cohort of animals (A, panel v; B, 
graph v). Statistics are based on One-way analysis of variance with Newman-Keuls Multiple 
Comparison Test. 
 
Figure 5. Representative images of astrogliosis and synaptopathy associated with 
increasing accumulation of misfolded PrPSc in nonTg ME7-, Prdx6 KO ME7- and Prdx6 Tg 
ME7-animals. (A-C) anti-GFAP antibody (shows increased numbers of activated 
astrocytes), (E-G) anti-Synaptophysin antibody shows loss of demarcated synaptic layers 














presynaptic marker protein in nonTg ME7- and Prdx6 KO ME7-animals while a more intact 
synaptic architecture is revealed in Prdx6 Tg ME7-animals. These markers of prion-related 
pathology were all exacerbated in Prdx6 KO ME7-animals compared to Prdx6 Tg ME7-
animals. No neuropathological differences were seen in Prdx6 KO NBH- and Prdx6 Tg 
NBH-animals (not shown here). Minus antibody control staining was also carried out (not 
shown). (D) We used ImageJ software (http://rsb.info.nih.gov/ij) to semi-quantitatively score 
histopathology staining and express it as a percent IR in Prdx6 KO ME7 and Prdx6 Tg ME7 
relative to IR in similarly stained sections from nonTg ME7-animals (n = 3). Using this 
approach there was a significant decrease in GFAP IR in the hippocampus of Prdx6 Tg 
ME7 compared to Prdx6 KO (p<0.001) and nonTg ME7-animals (p<0.001). (H) 
Synaptophysin IR was significantly reduced in the hippocampus of nonTg ME7 (p<0.001) 
and Prdx6 KO ME7 (p<0.001) compared to Prdx6 Tg ME7-animals, but there was also a 
difference in synaptophysin IR in nonTg ME7 compared to Prdx6 KO ME7-animals. 20x 
mag, and scale bar is 100 µm. (I) Serves to show the demarcation of the synaptic layers 
discussed in the text. DAB staining of the representative image in (G) was identified using 
ImageJ software, the Colour Deconvolution plugin was used to eliminate haematoxylin 
counterstain, and the image threshold was adjusted. Representative images are from 
coronal sections showing hippocampal region, stratum pyramidal (Spy), stratum radiatum 




















































































Induction of antioxidant Prdx6 is associated with astrogliosis in a prion disease. 
 
Treatment with TAT-Prdx6 rescues oxidative stress and cellular hypoxia in vitro. 
 
Prion-related neuropathology is exacerbated in antioxidant Prdx6 knock-out mice. 
 
Overexpression of antioxidant Prx6 in vivo attenuates prion-related neuropathology. 
 
Augmentation of Prdx6 represents an attractive adjunct therapeutic approach. 
 
